Merck & Co. Inc., of Kenilworth, N.J., fell 1 percent short of expectations in the fourth quarter of 2016, mainly blamed on lower sales of Januvia/Janumet (sitagliptin), Zetia (ezetimibe), Zostavax (zoster vaccine live) and Cubicin (daptomycin), though sales of PD-1 inhibitor Keytruda (pembrolizumab), at $483 million, marginally beat the consensus guess of $470 million.